On May 13, 2022, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Mounjaro (tirzepatide), a once-weekly injection for the treatment of type 2 diabetes mellitus (T2DM). Pathophysiology of Type 2 Diabetes Mellitus Incretins are the...
While Dipeptidyl Peptidase-4 (DPP4) inhibitors aren’t used incredibly often, we wanted to provide a comparison of DPP4 inhibitors. DPP4 inhibitors are used in the treatment of diabetes and function by inhibiting the breakdown of endogenous incretin hormones...
You’ve likely encountered numerous patients with hyperglycemia. A challenging situation that often comes up in practice is the loss of blood sugar control from a patient who had previously been well controlled. Your first step would be to inquire about...
With insulin products continually coming to market, it can be challenging to stay current with the new information. Here is a brief overview of newly approved insulin products in the last few years, some highlights that might make them unique, and how to switch...
I was asked about the clinical of thiazides and hyperglycemia. To be honest, studies aren’t that great surrounding this question, and the main ones I’m aware of and could find were very old. Here’s a quick breakdown of a couple of studies on the risk...
There may be a new option on the horizon for current insulin users! Insulin icodec is a new insulin option currently undergoing clinical trials. The most recent trial released for insulin icodec came out in November of 2020. The trial looked at the new insulin icodec,...
